{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:50:32Z","timestamp":1766040632130,"version":"3.48.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K01 DK118005"],"award-info":[{"award-number":["K01 DK118005"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine if combining PET-derived beta-cell mass (BCM) estimates with MRI-based morphology metrics improves the prediction of beta-cell functional mass in type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a retrospective analysis of 40 participants\u201419 T2D individuals, 16 healthy obese volunteers (HOVs), and five prediabetes individuals\u2014who underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]FP-(+)-DTBZ PET to quantify vesicular monoamine transporter type 2 (VMAT2) density [standardized uptake value ratio (SUVR-1)], T1-weighted MRI for 3D morphology metric analysis, and an arginine stimulation test to measure acute (AIRarg) and maximum (AIRargMAX) insulin responses. Least Absolute Shrinkage and Selection Operator (LASSO) regression models identified the optimal combination of positron emission tomography (PET), MRI, and clinical variables to predict beta-cell function for the whole pancreas and its subregions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to HOVs, individuals with T2D exhibited significantly reduced AIRarg and AIRargMAX. Only the pancreas body volume was significantly smaller in the T2D cohort. For the whole pancreas, a model including PET-derived SUVR-1 and a subset of clinical covariates best predicted acute beta-cell function (AIRarg). However, predicting maximum functional reserve (AIRargMAX) required the addition of MRI-based morphology metrics in combination with SUVR-1 and a subset of clinical covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We combined PET imaging of BCM and MRI morphology metrics with a robust machine learning-based variable selection method to extract useful PET- and MRI-based metrics for predicting acute and maximum insulin responses. This synergistic approach offers a novel combination of biomarkers for staging disease and evaluating therapeutic interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1724340","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:45:48Z","timestamp":1766040348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Morphological and functional alterations in type 2 diabetes pancreata assessed with MRI-based metrics and [18F]FP-(+)-DTBZ PET"],"prefix":"10.3389","volume":"16","author":[{"given":"Seyed Faraz","family":"Nejati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faranak Ebrahimian","family":"Sadabad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Bini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30022-X","article-title":"Personal View Inadequate \u03b2-cell mass is essential for the pathogenesis of type 2 diabetes","volume":"8","author":"Weir","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0126825","DOI":"10.1371\/journal.pone.0126825","article-title":"Altered volume, morphology and composition of the pancreas in type 2 diabetes","volume":"10","author":"Macauley","year":"2015","journal-title":"PloS One"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4624-0","article-title":") Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging","volume":"61","author":"Cline","year":"2018","journal-title":"Diabetologia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30303-X","article-title":"2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial","volume":"8","author":"Al-Mrabeh","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0180911","article-title":"Pancreatic size and fat content in diabetes: A systematic review and meta-analysis of imaging studies","volume":"12","author":"Garcia","year":"2017","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.1.102","article-title":"\u03b2-cell deficit and increased \u03b2-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"B7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1463-1326.2008.00969.x","article-title":"Pancreatic \u03b2-cell mass in European subjects with type 2 diabetes","volume":"10","author":"Rahier","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2849","article-title":"Elevations in the fasting serum proinsulin\u2013to\u2013C-peptide ratio precede the onset of type 1 diabetes","volume":"39","author":"Sims","year":"2016","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2625","article-title":"Proinsulin secretion is a persistent feature of type 1 diabetes","volume":"42","author":"Sims","year":"2019","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06003-5","article-title":"High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment","volume":"66","author":"Sims","year":"2023","journal-title":"Diabetologia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0995","article-title":"Exocrine pancreatic enzymes are a serological biomarker for type 1 diabetes staging and pancreas size","volume":"70","author":"Ross","year":"2021","journal-title":"Diabetes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0931","article-title":"Standardized mixed-meal tolerance and arginine stimulation tests provide reproducible and complementary measures of \u03b2-cell function: results from the foundation for the national institutes of health biomarkers consortium investigative series","volume":"39","author":"Shankar","year":"2016","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00149.2014","article-title":"Arginine is preferred to glucagon for stimulation testing of \u03b2-cell function","volume":"307","author":"Robertson","year":"2014","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0690","article-title":"Assessment of \u03b2-cell mass and \u03b1- and \u03b2-cell survival and function by arginine stimulation in human autologous islet recipients","volume":"64","author":"Robertson","year":"2015","journal-title":"Diabetes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.197285","article-title":"Evaluation of PET brain radioligands for imaging pancreatic \u03b2-cell mass: potential utility of 11 C-PHNO","volume":"59","author":"Bini","year":"2018","journal-title":"J Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234013","article-title":"PET imaging of pancreatic dopamine D2 and D3 receptor density with 11C-(+)-PHNO in type 1 diabetes","volume":"61","author":"Bini","year":"2020","journal-title":"J Nucl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.2967\/jnumed.121.262506","article-title":"Glucagonlike peptide-1 receptor imaging in individuals with type 2 diabetes","volume":"63","author":"Eriksson","year":"2022","journal-title":"J Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05830-2","article-title":"Importance of beta cell mass for glycaemic control in people with type 1 diabetes","volume":"66","author":"Jansen","year":"2023","journal-title":"Diabetologia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3166-3","article-title":"Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin","volume":"57","author":"Brom","year":"2014","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/me.2013-1083","article-title":"Minireview: Dopaminergic regulation of insulin secretion from the pancreatic islet","volume":"27","author":"Ustione","year":"2013","journal-title":"Mol Endocrinol Baltim Md"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.054866","article-title":"11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls","volume":"50","author":"Goland","year":"2009","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.100545","article-title":"In vivo imaging of endogenous pancreatic -cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET","volume":"53","author":"Normandin","year":"2012","journal-title":"J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s11307-015-0888-7","article-title":"Cross-sectional and test-retest characterization of PET with [18F]FP-(+)-DTBZ for \u03b2 Cell mass estimates in diabetes","volume":"18","author":"Freeby","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-018-1170-6","article-title":"Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of [18F]FP-DTBZ in healthy subjects and patients with type 1 diabetes","volume":"20","author":"Naganawa","year":"2018","journal-title":"Mol Imaging Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2006.07.002","article-title":"Visualizing pancreatic \u03b2-cell mass with [11C]DTBZ","volume":"33","author":"Simpson","year":"2006","journal-title":"Nucl Med Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27645","article-title":"Longitudinal noninvasive PET-based \u03b2 cell mass estimates in a spontaneous diabetes rat model","volume":"116","author":"Souza","year":"2006","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-010-0406-x","article-title":"Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes","volume":"13","author":"Singhal","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-024-04310-y","article-title":"Cross-sectional imaging of the pancreas in diabetes","volume":"49","author":"Virostko","year":"2024","journal-title":"Abdom Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000001054","article-title":"Imaging abnormalities of the pancreas in diabetes: implications for diagnosis and treatment","volume":"40","author":"Spilseth","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad150","article-title":"Longitudinal MRI shows progressive decline in pancreas size and altered pancreas shape in type 1 diabetes","volume":"108","author":"Wright","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2337\/dc23-1681","article-title":"Longitudinal assessment of pancreas volume by MRI predicts progression to stage 3 type 1 diabetes","volume":"47","author":"Virostko","year":"2024","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"crossref","first-page":"e15734056304038","DOI":"10.2174\/0115734056304038240515101952","article-title":"Risk prediction of type 2 diabetes mellitus by MRI-based pancreaticMorphology and clinical characteristics: A cross-sectional study","volume":"20","author":"Yan","year":"2024","journal-title":"Curr Med Imaging Rev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e15111","DOI":"10.1111\/dme.15111","article-title":"Non-invasive imaging of functional pancreatic islet beta-cell mass in people with type 1 diabetes mellitus","volume":"40","author":"Joshi","year":"2023","journal-title":"Diabetes Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600493","article-title":"Consensus nomenclature for in vivo imaging of reversibly binding radioligands","volume":"27","author":"Innis","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/db23-0009","article-title":"Exocrine pancreas in type 1 and type 2 diabetes: different patterns of fibrosis, metaplasia, angiopathy, and adiposity","volume":"73","author":"Wright","year":"2024","journal-title":"Diabetes"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e67454","DOI":"10.1371\/journal.pone.0067454","article-title":"Regional differences in islet distribution in the human pancreas - preferential beta-cell loss in the head region in patients with type 2 diabetes","volume":"8","author":"Wang","year":"2013","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.1038\/s41598-019-41891-x","article-title":"A novel optical tracer for VMAT2 applied to live cell measurements of vesicle maturation in cultured human \u03b2-cells","volume":"9","author":"Pecic","year":"2019","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01171-z","article-title":"Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors","volume":"11","author":"Aslanoglou","year":"2021","journal-title":"Transl Psychiatry"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1724340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:45:49Z","timestamp":1766040349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1724340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":38,"alternative-id":["10.3389\/fendo.2025.1724340"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1724340","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1724340"}}